How Long After Rituximab Ends Does Hepatitis B Prophylaxis Actually Need to Continue
A single patient, finishing her last cycle of rituximab-based chemotherapy for lymphoma, hepatitis-B core-antibody positive but surface-antigen negative. The disagreement isn't whether she needed prophylaxis — it's when it's actually safe to stop it.
W.C., a 55-year-old high school librarian, is finishing her sixth and final cycle of rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma, diagnosed eight months ago after months of unexplained night sweats she'd initially blamed on menopause; interim imaging shows a complete metabolic response, so everything now under discussion is about protecting a remission she has already earned rather than about her lymphoma. Pre-chemotherapy screening found her hepatitis B surface antigen negative but core antibody positive — evidence of a hepatitis B infection she cleared decades ago, likely without ever knowing she'd had it, and never with any surface-antigen-positive disease of her own. That serologic pattern doesn't mean the virus is gone; hepatitis B can persist as covalently closed circular DNA in hepatocytes indefinitely after apparent clinical resolution, controlled by ongoing immune surveillance rather than eliminated outright — surveillance that rituximab, by depleting the B cells responsible for maintaining protective antibody production, specifically removes.
She started entecavir prophylaxis alongside her first chemotherapy cycle, which everyone on her care team agreed on without debate — AASLD's hepatitis B guidance classifies anti-CD20 therapy as high risk for HBV reactivation in a core-antibody-positive patient, regardless of baseline viral load, precisely because rituximab's B-cell-depleting effect targets the surveillance mechanism directly. The genuine disagreement, arriving now that her last chemotherapy dose is scheduled for next week, is how long prophylaxis needs to continue afterward. Reactivation risk with rituximab specifically doesn't end when the drug does — B-cell reconstitution takes months, sometimes closer to a year, and reactivation events have been documented well after chemotherapy completion, later than the shorter windows used for less B-cell-specific regimens. Which means the variable that should govern the stopping date is not the calendar at all. It is her B-cell count — the compartment rituximab removed, the compartment the reactivation risk tracks, and, unlike a month, something that can be measured.
Oncology/hepatology co-visit, final cycle week
I'd continue entecavir for a full 18 months past her last rituximab dose, not the shorter 6-to-12-month window used for regimens without a B-cell-depleting agent. AASLD's guidance sets a longer floor after B-cell-depleting therapy than after other regimens for exactly this reason, and reactivation after rituximab has been documented well past chemotherapy completion, tracking B-cell reconstitution timelines rather than how quickly the drug itself clears — and reactivation in this setting can be severe, sometimes fulminant.
Eighteen months is not a number I can point to a trial for, and I want that on the record before anyone treats it as one.
I'd stop at 12 months, the standard post-completion window for most anti-CD20 regimens. I don't dispute that her reactivation risk outlasts a non-rituximab regimen's — I'm disputing that 18 months specifically, rather than 12, is the proven right duration. Extending further adds real cost and long-term drug exposure without a dedicated comparative trial showing 18 outperforms 12.
I take the delayed-reactivation pattern seriously — I'm just not convinced the specific number 18 is more than an educated extrapolation from that pattern, rather than something actually validated against 12 head-to-head.
I'd sidestep the calendar argument entirely and use a direct measurement instead: check her B-cell reconstitution status periodically after 12 months, and stop prophylaxis once reconstitution is confirmed rather than at a fixed month either of you is defending. Reconstitution, not elapsed time, is the actual biological variable driving her risk.
That approach doesn't resolve which fixed number is "more correct" — it makes the fixed-number debate less necessary, since we'd be stopping based on evidence her own risk has actually declined rather than an average timeline applied to her specifically.
Agreed: entecavir continues past chemotherapy completion, with B-cell reconstitution checked starting at the 12-month mark and prophylaxis continued until reconstitution is confirmed rather than stopped at a fixed date regardless of her actual status.
Not fully resolved: whether 12 or 18 months would have been the "right" fixed duration in the absence of reconstitution testing remains genuinely unsettled between the hepatologist and oncologist, and the team was explicit that today's plan sidesteps that disagreement rather than resolving it — if reconstitution testing weren't available to a future patient, this exact debate would need to be revisited on its own terms.